Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CERS 
Cerus Corporation (CERS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: CERS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.67
1 Year Target Price $4.67
| 4 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.13% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 282.92M USD | Price to earnings Ratio - | 1Y Target Price 4.67 |
Price to earnings Ratio - | 1Y Target Price 4.67 | ||
Volume (30-day avg) 5 | Beta 1.54 | 52 Weeks Range 1.12 - 2.54 | Updated Date 07/2/2025 |
52 Weeks Range 1.12 - 2.54 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.23% | Operating Margin (TTM) -13.54% |
Management Effectiveness
Return on Assets (TTM) -3.82% | Return on Equity (TTM) -35.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 288063276 | Price to Sales(TTM) 1.53 |
Enterprise Value 288063276 | Price to Sales(TTM) 1.53 | ||
Enterprise Value to Revenue 1.56 | Enterprise Value to EBITDA -13.19 | Shares Outstanding 191160000 | Shares Floating 165506744 |
Shares Outstanding 191160000 | Shares Floating 165506744 | ||
Percent Insiders 3.35 | Percent Institutions 76.13 |
Upturn AI SWOT
Cerus Corporation
Company Overview
History and Background
Cerus Corporation was founded in 1991. Initially focused on protein research, it transitioned to blood safety technology, achieving significant milestones with INTERCEPT Blood System approvals in Europe and the US.
Core Business Areas
- Blood Safety: Develops and commercializes the INTERCEPT Blood System, a technology designed to inactivate pathogens in blood components (platelets, plasma, and red blood cells) used for transfusions. This reduces the risk of transfusion-transmitted infections.
Leadership and Structure
Cerus is led by William 'Obi' Greenman (President and CEO). The organizational structure is functional, with departments for R&D, manufacturing, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- INTERCEPT Blood System: A pathogen reduction technology for blood components. It inactivates a broad range of viruses, bacteria, parasites, and leukocytes in platelets, plasma, and red blood cells. Competitors are companies using bacterial detection methods or other pathogen inactivation technologies. It is challenging to obtain precise market share data, but INTERCEPT has a significant presence in regions where pathogen reduction is mandated or highly recommended. Revenue is dependent on system adoption by blood banks and hospitals.
Market Dynamics
Industry Overview
The blood safety market is driven by the need to reduce transfusion-transmitted infections and improve patient safety. Regulatory mandates and hospital adoption are key drivers. The market is growing due to increasing awareness and emerging infectious diseases.
Positioning
Cerus is a leader in pathogen reduction technology for blood components. Its competitive advantage lies in its broad-spectrum pathogen inactivation capabilities and regulatory approvals.
Total Addressable Market (TAM)
The TAM is estimated to be in the billions of dollars, encompassing all blood components used in transfusions globally. Cerus's position is strong in markets with pathogen reduction mandates, but it aims to expand further into regions with less stringent regulations. Current market adoption is estimated to be less than 20% of the total potential transfusion market for pathogen reduction
Upturn SWOT Analysis
Strengths
- FDA-approved technology
- Broad-spectrum pathogen inactivation
- Established presence in key markets
- Growing regulatory support for pathogen reduction
Weaknesses
- High cost of INTERCEPT system compared to alternatives
- Dependence on regulatory mandates for market adoption
- Limited product portfolio beyond blood safety
- Variable adoption rates across different regions
Opportunities
- Expansion into new geographic markets
- Development of new applications for INTERCEPT technology
- Partnerships with blood banks and hospitals
- Increasing awareness of transfusion-transmitted risks
Threats
- Competition from alternative blood safety technologies
- Resistance from blood banks due to cost concerns
- Changes in regulatory landscape
- Emergence of new blood-borne pathogens
Competitors and Market Share
Key Competitors
- Baxalta (now Takeda) (TAK)
- Grifols (GRFS)
Competitive Landscape
Cerus competes with companies offering alternative blood safety technologies. Its key advantage is its broad-spectrum pathogen inactivation. Disadvantages include high cost versus other blood screening technologies.
Growth Trajectory and Initiatives
Historical Growth: Cerus has experienced revenue growth driven by increased adoption of INTERCEPT in key markets.
Future Projections: Analysts project continued revenue growth as pathogen reduction becomes more widely adopted. Profitability is expected to improve over time.
Recent Initiatives: Cerus is focusing on expanding its market presence in the US and other regions. They are also working on new applications for the INTERCEPT technology.
Summary
Cerus Corporation is a key player in the blood safety market with its INTERCEPT technology. While it faces challenges related to cost and market adoption, its broad-spectrum pathogen inactivation capabilities provide a competitive advantage. The company is growing revenue but still operating at a loss. Continued expansion and strategic partnerships will be crucial for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Analyst Reports, Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cerus Corporation
Exchange NASDAQ | Headquaters Concord, CA, United States | ||
IPO Launch date 1997-01-30 | CEO - | ||
Sector Healthcare | Industry Medical Devices | Full time employees 614 | Website https://www.cerus.com |
Full time employees 614 | Website https://www.cerus.com | ||
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.